drugset / Trial / NCT03425461
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Phase 1
Terminated
6 enrolled
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb · collabNational Cancer Institute (NCI) · collabVaccinex Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized pilot phase I trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 when given together with nivolumab or ipilimumab in treating patients with stage III or IV melanoma. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Timeline
- Start
- 2018-06-14
- Primary completion
- 2021-03-04
- Completion
- 2021-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Pepinemab | Monoclonal antibody | — | Intravenous |